- University of Wisconsin School of Medicine and Public Health - MD
- University of Wisconsin Hospital and Clinics - Residency in Internal Medicine
- University of Wisconsin Hospital and Clinics - Fellowship in Medical Oncology
- University of Wisconsin-Madison - Research Fellowship (T32 Training Grant) under the direction of Douglas McNeel, MD, PhD (principal investigator) and Richard Halberg, PhD (mentor)
Dr. Dustin Deming is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care. As clinician, his primary focus is on medical care of patients living with gastrointestinal cancers including colorectal cancer and esophageal cancer. He serves as Clinical Co-Chair of the UW Carbone Cancer Center (UW CCC) Molecular Tumor Board, as Director and Founder of the UW CCC Colorectal and Anal Cancer Working Group (CRAWG), as Vice Chair of the Chemotherapy Council, and as Medical Director of the William S. Middleton Memorial Hospital Oncology Infusion Clinic. As a physician-scientist, Dr. Deming’s research program focuses on developing precision medicine treatments for different subtypes of colon cancer. As a medical educator, he provides classroom and clinical instruction to medical students, residents, fellows, and other oncology providers. Honors and awards bestowed upon Dr. Deming include being named to the Best Doctors in America list on multiple occasions, being designated as UW Health Patient Experience Physician Champion on the basis of patient satisfaction, and being appointed as Young Investigator to the National Cancer Institute's Rectal and Anal Cancer Task Force. Dr. Deming is a member of American Association of Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the Eastern Cooperative Oncology Group (ECOG-ACRIN), the Big Ten Cancer Research Consortium (B1G CRC), and serves as an advisory board member of Fight Colorectal Cancer (FCC).
Dr. Deming’s clinical specialties include medical oncology with emphasis on gastrointestinal cancer (colon cancer, rectal cancer, anal cancer, esophageal cancer, liver cancer, and pancreatic cancer).
Dr. Deming’s research program focuses on developing treatments for subtypes of colon cancer and other gastrointestinal cancers using animal models to test personalized regimens for patients based on each patient’s tumor mutations. His laboratory has developed 3-dimensional cell culture techniques for clinical cancer research. He also leads work to identify new and improved biomarkers. Dr. Deming’s research has been funded by the National Institute of Health – National Cancer Institute (NIH-NCI), The V Foundation, the UW Carbone Cancer Center, the Wisconsin Partnership Program, and the American Cancer Society, among others.